Cell viability, apoptosis and cell cycle assays were performed to determine whether SOX9 contributes to DLBCL chemoresistance and rescues silencing IRF4‐induced phenotypes. The gene discussed is IRF4; the disease is diffuse large B-cell lymphoma.